Investors & Partners (eng)

Amynon's close links to scientific institutions and its market orientation by focusing on areas with a high market potential, strong patent position, and the promising pipeline makes Amynon an ideal partner for collaborative ventures and investments.

The Amynon Biotech GmbH team consist of scientists who have years of professional experience in research and research organisations. The resulting intense scientific cooperation with national and international academic groups allows faster access to new targets and reinforces continuously the existing know-how advantage.

Beside that, Amynon follows an active approach to establish itself in the market. Amynon participated in the business plan competitions "AdventureX" and "Best of Biotech (2001)" and won the "Tyrolean Young Entrepreneur Award (2003)". The company is listed on the co-operation platforms of the Bureau of International Research and Technology cooperation (BIT) and the German Diagnostic Association (VDGH). Amynon is also a member of the cluster initiatives of the Competence Center Tyrol (KMT) and Munich Network.

Scientific Cooperation

Amynon keeps close contact with several research associations, in particular the Tyrolean Cancer Research Institute (TKFI), the Austrian Academy of Science (OEAW), the University of Innsbruck and University Hospital Innsbruck. Besides that, Amynon is the commercial partner of 'CELLAGE', an European Union Program.

Commercial Partners

As a science-based and market oriented company Amynon is permanently interested in international cooperations with diagnostic and pharmaceutical companies to further develop and commercialise Amynon's products.

Due to its innovative approach, which is based on the latest scientific results, the proximity of the products to market demand and a strong patent position, Amynon is an interesting partner.

Investors

To realize its innovative business concept Amynon Biotech received seed financing from the 'Innovationsagentur' with its head office in Vienna as well as a regional grant from the 'Tiroler Zukunftsstiftung'.

For several reasons an engagement in Amynon Biotech can be of interest: The proximity to scientific research and the integration in several European scientific cooperations allow an ongoing access to upcoming trends and new areas of knowledge. The strong patent position provides a competitive advantage and the freedom to operate. The technology platform is scaleable and the products fulfill the needs of patients, doctors and insurance companies. An early product placement allows first income, while the focussed indications promise considerable market potential.

Sitemap / Imprint / Deutsche Version

© 2005 & hosting webfeeling | Prugger & Reisenberger